Loading…
← CockpitCompetitor Analysis › 2142.HK HBM Holdings Ltd.Open in the cockpit ↗

HBM Holdings Ltd.2142.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Pharmaceuticals: Other

Biotech using proprietary transgenic-mouse antibody platforms (Harbour Mice) to discover and license novel antibody drugs.

≈ A Chinese/global antibody-discovery platform biotech, akin to a smaller Regeneron licensorMomentum weak 34
Mkt cap
$1.12B
US dollars, full cap
Free float
68%
of shares outstanding
$/day
$9.98M
20-day average traded
Fwd P/E
11.7×
forward earnings
ROIC−WACC
+30.2 pp
WACC 14.5%
Hurdle
-49 pp
Req g minus delivered
Next earnings
133 days
31 Mar 2027
Close · HKDHK$10.08
1D-0.2%
1W-10.4%
1M-3.6%
3M-30.4%
6M-18.2%
YTD-17.1%
1Y-22.8%
ATR %6.1%
52w lowhigh41.0% off high

What HBM does

Biotech using proprietary transgenic-mouse antibody platforms (Harbour Mice) to discover and license novel antibody drugs.

Earns mainly by licensing its antibody platform and drug candidates to pharma partners, receiving upfront payments, milestones and later royalties, rather than selling its own medicines, so income arrives in lumps tied to deals.

In one line: A Chinese/global antibody-discovery platform biotech, akin to a smaller Regeneron licensor.

Products and services

  • Harbour Mice antibody discovery platform
  • In-house oncology/immunology antibody pipeline

Customers

  • Global pharma licensing partners
  • Hospitals (post-approval)

Where it sits in the supply chain

  • Biotechnology
  • Antibody discovery platforms
  • Licensed/co-developed biologics

What could go right

  • Platform licensing revenue
  • Pipeline co-development deals

What could go wrong

  • Clinical trial risk
  • Reliance on partner milestone payments

Moat: narrow (IP / patents, process know-how). Proprietary transgenic mouse platforms for fully human antibody discovery.

Headquarters: Shanghai, China / Rotterdam · Founded: 2016 · Employees: 272

Named competitors

HBM at a glance

Size HBM (2142.HK) is a Hong Kong Health Care company (Pharmaceuticals: Other) with a market value of $1.12B, the 553rd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$10.08 on 18 Nov 2026.

Performance Over six months the shares fell 18.2%, against -9.8% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue grew 55.3% over the last twelve months (peer median +4.6%); the operating margin is 44.4% (peer median 14.4%).

Valuation It trades at 11.7× forward earnings against a peer median of 18.4× (6th cheapest of 17).

Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +62%, so the hurdle is -49 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 30.2 points above its cost of capital (14.5% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026Peer median 902142.HK 85
Six months, rebased to 100: HBM against the median of its 20 peers (local-currency closes).

HBM financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$1.40BHK$1.23BHK$297MHK$701MHK$318M
Revenue growth—+314%-58%+120%—
Gross profitHK$1.30BHK$1.15BHK$240MHK$649MHK$254M
EBITDAHK$651MHK$648M-HK$6.32MHK$203M-HK$892M
Net incomeHK$661MHK$712MHK$21.7MHK$178M-HK$1.07B
Free cash flowHK$51.3MHK$653MHK$264M-HK$153M-HK$912M
Capital expenditureHK$114MHK$91.6MHK$1.83MHK$19.4MHK$144M
Total debtn/aHK$636MHK$476MHK$515MHK$710M

Quarterly statements and history in the cockpit →

HBM competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%CRON002275PHM0719BIOG-B6472APNJWEL002219PHNSUDEEPPHRM046060326260021600228728773007913003636004883000392142.HK6-month return →1-month return →
Up and to the right = strong over both horizons. HBM is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×100×CRON002275PHM0719BIOG-B6472APNJWEL002219SUDEEPPHRM046060326228773007912142.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. HBM is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%CRON002275PHM0719BIOG-B6472APNJWELPHN6032626002163007916004883000392142.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. HBM is the large dot.

HBM competitors and peer comparison

Head to head with its named competitors (2142.HK vs REGN vs 2269.HK vs 1801.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
HBM 2142.HK$1.12B-18%+55%44%11.7×13.1%
Regeneron Pharmaceuticals REGN$97.8B+46%+19%30%11.8×-1.1%
Wuxi Bio 2269.HK$23.1B+35%+22%32%26.5×20.8%
Innovent Biologics 1801.HK$18.9B+4%+43%17%52.3×11.6%

How HBM compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

HBM against its 20 peers (data as of 18 Nov 2026)
Measure2142.HKPeer medianRank in peer set
1-month return-3.6%-3.6%11th highest of 21
6-month return-18.2%-9.8%9th lowest of 21
Distance from 52-week high-41.0%-33.5%7th lowest of 21
Revenue growth (TTM)+55.3%+4.6%highest of 21
Operating margin44.4%14.4%highest of 21
Forward P/E11.7×18.4×6th cheapest of 17
Growth the price implies (Req g, 7 yrs)13.1%2.8%6th most demanding of 17
Growth delivered (Del g)+62.3%+11.9%highest of 17
Hurdle (Req g minus delivered)-49.2 pp-8.8 pp2nd least demanding of 17
ROIC minus cost of capital+30.2 pp+2.5 pp3rd highest of 21
EV / EBITDA10.2×18.9×2nd cheapest of 10
Net debt / EBITDA-3.2×-0.7×3rd least indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
HBM 2142.HKHong Kong$1.12B-18%+55%44%11.7×13.1%+62.3%
Cronos CRON.TOCanada$1.17B+24%+55%5%16.2×18.8%+26.7%
Guilin Sanjin Pharmaceutical 002275.SZChina$1.05B-12%-3%24%12.8×-8.7%+5.5%
Pharma Mar PHM.MCSpain$1.21B-38%+32%19%41.4×10.6%-3.9%
Shandong Xinhua Pharmaceutical 0719.HKHong Kong$1.03B-19%-1%4%6.2×-2.1%+7.1%
BioGaia BIOG-B.STSweden$1.25B-4%+13%28%31.0×1.5%+15.5%
Bora Pharmaceuticals 6472.TWTaiwan$1.25B-2%+7%14%10.8×3.5%+60.2%
Applied Nutrition APN.LUnited Kingdom$986M+31%+51%25%21.4×24.6%+38.5%
Jamieson Wellness JWEL.TOCanada$1.32B+32%+12%13%20.6×13.5%+15.3%
New Journey Health Technology Group Co., Ltd.Class A 002219.SZChina$942M-18%-14%8%182.0×n/an/a
PharmaNutra PHN.MIItaly$922M+2%+17%22%33.5×4.7%+18.5%
Sudeep Pharma SUDEEPPHRM.NSIndia$1.45B+85%+27%33%69.1×n/an/a
Sihuan Pharmaceutical 0460.HKHong Kong$856M-34%+30%15%8.7×n/an/a
TSI 603262.SSChina$842M-46%+3%14%47.7×24.3%+13.4%
Zhejiang Medicine 600216.SSChina$1.51B-26%-6%7%11.5×-7.8%+3.9%
Tibet Cheezheng Tibetan Medicine 002287.SZChina$1.58B-17%-7%28%n/a-1.9%+10.4%
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%7.6×n/an/a
Sirio Pharma 300791.SZChina$759M-6%-9%1%16.2×14.1%+15.6%
Porton Pharma Solutions 300363.SZChina$1.66B+37%+6%-2%n/a2.1%+10.4%
Tianjin Tianyao Pharmaceuticals 600488.SSChina$718M-36%-12%3%n/a2.1%-1.3%
Shanghai Kaibao Pharmaceutical 300039.SZChina$703M-20%-14%22%n/a0.4%+4.8%

Questions

Who are HBM's main competitors?
Named competitors: Regeneron Pharmaceuticals (REGN), WuXi Biologics (2269.HK), Innovent Biologics (1801.HK). The cockpit's measured peer set (industry) also includes Cronos (CRON.TO), Guilin Sanjin Pharmaceutical (002275.SZ), Pharma Mar (PHM.MC), Shandong Xinhua Pharmaceutical (0719.HK), BioGaia (BIOG-B.ST), Bora Pharmaceuticals (6472.TW).
Is HBM expensive compared with its peers?
On forward p/e it trades at 11.7× against a peer median of 18.4×, 6th cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +62%, so the hurdle is -49 pp: the price already allows for a slowdown.
How has HBM stock performed?
Over six months to 18 Nov 2026 the shares returned -18.2% against -9.8% for the median peer; over one year -22.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.